Ultragenyx's (RARE) XLH Drug Positive In Phase II Study
Zacks Investment Research | Apr 09, 2017 09:34PM ET
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23). It is being developed for the treatment of X-linked hypophosphatemia (XLH) in children aged five to twelve years of age.
The multicentre, open-label, dose-finding phase II study (n=52) showed improvement in serum phosphorus levels, rickets, growth rates and other functional outcomes with use of KRN23, sustained through 64 weeks of treatment.
Additionally, a separate phase II study (n=13) evaluating KRN23 patients aged one to five years demonstrated that KRN23 increased serum phosphorus levels in the low normal range.
Ultragenyx’s share price movement shows that the stock has significantly underperformed the Zacks classified Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.